Key Findings
On August 27, 2026, Epocrates detailed the introduction of Abbott’s newly authorized Libre Duo 10 Day system as the first wearable device to integrate both continuous glucose monitoring (CGM) and ketone tracking. This groundbreaking system significantly aids in the prevention of diabetic ketoacidosis (DKA) by providing real-time ketone trend data in conjunction with glucose readings, especially for patients at high risk of DKA. This integration promises to dramatically enhance diabetes patient self-management and foster a safer daily life.
Technical and Clinical Details
The Libre Duo 10 Day comprises a small, patch-type sensor worn on the patient’s skin, continuously measuring both blood glucose and beta-hydroxybutyrate (BHB)—the primary ketone body in blood. This dual-sensor technology enables the real-time tracking of dynamic changes in ketone levels, a capability that was challenging with conventional, intermittent measurements. A key clinical advantage highlighted by Epocrates is the system’s ability to automatically issue alerts before ketone levels reach a critical threshold. This feature is invaluable for healthcare professionals, providing a more comprehensive understanding of a patient’s metabolic state and facilitating timely therapeutic interventions or guidance, particularly during high-risk scenarios for DKA, such as sick days or insulin pump malfunctions. Such early warnings are crucial for reducing patient anxiety and preventing severe complications.
Background and Industry Context
For diabetes patients, especially those who are insulin-dependent, diabetic ketoacidosis (DKA) remains a serious threat. DKA occurs when insulin deficiency leads to the breakdown of body fat for energy, resulting in an abnormal accumulation of ketones. Conventional CGMs focused solely on glucose, requiring separate, often cumbersome tests for ketone monitoring. This gap in continuous data hindered early detection and prevention of DKA. Abbott’s Libre Duo 10 Day has been developed to address this critical medical need, establishing a new standard for integrated monitoring in diabetes care. This aligns with global healthcare trends shifting towards patient-centric preventive medicine.
Strategic Significance and Outlook
Epocrates anticipates that the introduction of Libre Duo 10 Day will have a profound impact on the future of diabetes management. The system empowers patients to gain a deeper understanding of their metabolic status, enabling them to more effectively adjust their lifestyle and treatment plans. Furthermore, within the context of Remote Patient Monitoring (RPM), healthcare providers will be able to evaluate comprehensive patient data in real-time, facilitating more efficient and personalized care delivery. From an investment perspective, the transformative potential of this technology in the diabetes treatment market, alongside the opportunities for market expansion, are noteworthy. Other biosensor companies are also expected to enter the competition to develop similar multi-functional devices.
Source: https://www.epocrates.com/online/article/ketone-tracking-joins-cgm-in-first-of-its-kind-wearable
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments